文献速递真菌感染

侵袭性霉菌感染早期治疗的临床考量

Clinical considerations in the early treatment of invasive mould infections and disease.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

本文综述了侵袭性真菌病的不同治疗策略,包括广谱抗真菌预防、经验性治疗和抢先治疗,分析各策略的优缺点。抗霉菌预防应限于高危人群;经验性治疗未显示全因死亡率获益但推荐用于高危持续发热中性粒细胞减少患者;抢先治疗成本更低且疗效未降低,可能适用于临床稳定的中性粒细胞减少发热患者。

要点

  • 抗霉菌预防仅限高危人群,如急性髓系白血病强化化疗、异基因HSCT后等。
  • 经验性治疗推荐用于广谱抗生素4-7天后仍发热且预期延长中性粒细胞减少的高危患者。
  • 抢先治疗成本更低且疗效未降低,可能适用于临床稳定的中性粒细胞减少发热患者。

核心结论

  • 抗霉菌预防应限制于高危人群,因广谱预防存在干扰诊断、选择耐药、药物毒性和相互作用等缺点。
  • 经验性治疗未显示全因死亡率获益,但推荐用于广谱抗生素4-7天后仍发热且预期延长中性粒细胞减少的高危患者。
  • 抢先治疗成本更低且现有证据未提示疗效降低,可能适用于广谱抗生素后仍发热但临床稳定的中性粒细胞减少患者。

研究设计与样本

  • 本文为综述,探讨侵袭性真菌病的不同治疗策略(预防、经验性治疗、抢先治疗)的临床考量。

主要发现

  • 广谱抗真菌预防存在干扰诊断试验、选择耐药、药物毒性和药物相互作用等显著缺点。
  • 经验性治疗带来过度治疗的临床和成本负担,且未显示全因死亡率获益。
  • 抢先治疗成本低于经验性治疗,现有证据未提示疗效降低。
  • 经验性与抢先方案的比较研究稀少,尤其涉及现代三唑类药物。

关键数值与推荐

  • 抗霉菌预防适用于:急性髓系白血病或骨髓增生异常综合征强化化疗患者、有侵袭性真菌感染史或移植物抗宿主病或延长中性粒细胞减少的异基因HSCT患者、实体器官移植受者、高风险遗传性免疫缺陷患者。
  • 经验性治疗推荐用于:广谱抗生素治疗4-7天后仍发热且预期延长中性粒细胞减少的高危患者。
  • 抢先治疗可能适用于:广谱抗生素后仍发热但临床稳定的中性粒细胞减少患者。

临床怎么用

  • 根据患者风险分层选择抗霉菌预防,避免低危患者不必要的广谱预防。
  • 对广谱抗生素4-7天后仍发热且预期延长中性粒细胞减少的高危患者启动经验性抗霉菌治疗。
  • 对临床稳定的中性粒细胞减少发热患者可考虑抢先治疗以降低成本。

局限性

  • 经验性与抢先方案的比较研究稀少,尤其缺乏现代三唑类药物的数据。
  • 需进一步研究明确各治疗策略的最佳患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Different therapeutic strategies for invasive fungal diseases have been explored, each with particular strengths and weaknesses. Broad-spectrum antifungal prophylaxis seems logical, but selective use is important due to its substantial disadvantages, including interference with diagnostic assays, selection for resistance, drug toxicity and drug-drug interactions. Antimould prophylaxis should be restricted to high-risk groups, such as patients undergoing intensive chemotherapy for acute myeloid leukaemia or myelodysplastic syndrome, allogeneic HSCT patients with prior invasive fungal infection, graft-versus-host-disease or extended neutropenia, recipients of a solid organ transplant, or patients with a high-risk inherited immunodeficiency. An empirical approach, whereby mould-active therapy is started in neutropenic patients with fever unresponsive to broad-spectrum antibiotics, is widely applied but incurs the clinical and cost penalties associated with overtreatment. A benefit for all-cause mortality using empirical therapy has not been shown, but it is recommended for high-risk patients who remain febrile after 4-7 days of broad-spectrum antibiotics and in whom extended neutropenia is anticipated. There is growing interest in delaying antifungal treatment until an invasive fungal infection is confirmed ('pre-emptive' or 'diagnostics-driven' management), prompted by the development of more sensitive diagnostic techniques. Comparisons of empirical versus pre-emptive regimens are sparse, particularly with modern triazole agents, but treatment costs are lower with pre-emptive therapy and the available evidence has not indicated reduced efficacy. Pre-emptive treatment may be appropriate in neutropenic patients who remain febrile after administration of broad-spectrum antibiotics but who are clinically stable. Further work is required to define accurately the specific patient subgroups in which each management approach is optimal.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mercier T, Maertens J. Clinical considerations in the early treatment of invasive mould infections and disease. J Antimicrob Chemother. 2017. PMID: 28355465. doi:10.1093/jac/dkx031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。